Nathan T. Ihle

2.4k total citations
23 papers, 1.5k citations indexed

About

Nathan T. Ihle is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nathan T. Ihle has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 5 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nathan T. Ihle's work include PI3K/AKT/mTOR signaling in cancer (18 papers), Protein Kinase Regulation and GTPase Signaling (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Nathan T. Ihle is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (18 papers), Protein Kinase Regulation and GTPase Signaling (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Nathan T. Ihle collaborates with scholars based in United States and Belgium. Nathan T. Ihle's co-authors include Garth Powis, Peter Wipf, Ryan Williams, D. Lynn Kirkpatrick, Amanda F. Baker, Robert T. Abraham, Margareta Berggren, Gillian Paine-Murrieta, Robert Lemos and Lynn Kirkpatrick and has published in prestigious journals such as Cell, Molecular Cell and Cancer Research.

In The Last Decade

Nathan T. Ihle

21 papers receiving 1.4k citations

Peers

Countries citing papers authored by Nathan T. Ihle

Since Specialization

Citations

This map shows the geographic impact of Nathan T. Ihle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan T. Ihle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan T. Ihle more than expected).

Fields of papers citing papers by Nathan T. Ihle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan T. Ihle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan T. Ihle. The network helps show where Nathan T. Ihle may publish in the future.

Co-authorship network of co-authors of Nathan T. Ihle

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan T. Ihle. A scholar is included among the top collaborators of Nathan T. Ihle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan T. Ihle. Nathan T. Ihle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer 2023 ·Molecular Cancer Therapeutics ·Catherine Lee, Ziyue Karen Jiang, Simon Planken, (unknown), Roberto Ortiz, Michael Hall, (unknown), Sripad Ram, Timothy Affolter, (unknown), Nathan T. Ihle, Theodore Johnson, Youngwook Ahn, Manfred Kraus, Anand Giddabasappa	0
2	An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors 2019 ·Cancer Research ·(unknown), (unknown), (unknown), Nathan T. Ihle, Geoffrey Grandjean, Michael J. Scott, Zamal Ahmed, Emmanuelle J. Meuillet, Shuxing Zhang, Robert Lemos, Lei Du‐Cuny, (unknown), Ricardo G. Correa, Laurie A. Bankston, Robert Liddington, Lynn Kirkpatrick, Garth Powis	23
3	Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer 2017 ·Cell ·Liron Bar‐Peled, Esther K. Kemper, Radu M. Suciu, Ekaterina V. Vinogradova, Keriann M. Backus, Benjamin D. Horning, Thomas A. Paul, Taka-Aki Ichu, Robert Svensson, José Olucha, Max W. Chang, Bernard P. Kok, Zhou Zhu, Nathan T. Ihle, Melissa M. Dix, Ping Jiang, Matthew M. Hayward, Enrique Sáez, Reuben J. Shaw, Benjamin F. Cravatt	195
4	The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration 2017 ·Molecular Cell ·Nathan T. Ihle, Robert T. Abraham	8
5	Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine 2016 ·BMC Genomics ·Zhou Zhu, Nathan T. Ihle, Paul A. Rejto, Patrick P. Zarrinkar	7
6	Differential Activity of the KRAS Oncogene by Method of Activation: Implications for Signaling and Therapeutic Intervention 2012 ·Experimental Eye Research ·Nathan T. Ihle	4
7	PI-3-Kinase Inhibitors in Colorectal Cancer 2011 ·Current Cancer Drug Targets ·Nathan T. Ihle, Garth Powis, Scott Kopetz	11
8	Abstract 4481: Topical application of the dual PDPK1/AKT inhibitor PHT-427 inhibits signaling and growth of human breast cancer cutaneous metastases in mice 2011 ·Cancer Research ·D. Lynn Kirkpatrick, J. L. Johnson, Robert Lemos, (unknown), Nathan T. Ihle, Garth Powis	1
9	Inhibitors of phosphatidylinositol-3-kinase in cancer therapy 2010 ·Molecular Aspects of Medicine ·Nathan T. Ihle, Garth Powis	33
10	The biological effects of isoform-specific PI3-kinase inhibition. 2010 ·PubMed ·Nathan T. Ihle, Garth Powis	10
11	Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor 2010 ·Molecular Cancer Therapeutics ·Emmanuelle J. Meuillet, Zuohe Song, Robert Lemos, Nathan T. Ihle, (unknown), Ryan Watkins, (unknown), Shuxing Zhang, Lei Du‐Cuny, Roy S. Herbst, Jörg J. Jacoby, Li Zhou, (unknown), Eugene A. Mash, D. Lynn Kirkpatrick, Garth Powis	66
12	In vitro and In vivo Activity of Novel Small-Molecule Inhibitors Targeting the Pleckstrin Homology Domain of Protein Kinase B/AKT 2009 ·Cancer Research ·(unknown), (unknown), Zuohe Song, Lei Du‐Cuny, Li Zhou, Robert Lemos, Nathan T. Ihle, A. Geoffrey Skillman, Shuxing Zhang, Eugene A. Mash, Garth Powis, Emmanuelle J. Meuillet	48
13	Discovery of a novel class of AKT pleckstrin homology domain inhibitors 2008 ·Molecular Cancer Therapeutics ·Daruka Mahadevan, Garth Powis, Eugene A. Mash, Benjamin L. George, Vijay Gokhale, Shuxing Zhang, Kishore Shakalya, Lei Du‐Cuny, Margareta Berggren, (unknown), Umasish Jana, Nathan T. Ihle, (unknown), (unknown), Satya Narayan, Nikhil Shirahatti, Emmanuelle J. Meuillet	63
14	Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance 2008 ·Cancer Research ·Nathan T. Ihle, Robert Lemos, Peter Wipf, Adly Yacoub, Clint Mitchell, Doris R. Siwak, Gordon B. Mills, Paul Dent, D. Lynn Kirkpatrick, Garth Powis	225
15	The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling 2006 ·Cancer Chemotherapy and Pharmacology ·Ryan Williams, Amanda F. Baker, Nathan T. Ihle, (unknown), Lynn Kirkpatrick, Garth Powis	25
16	Practicalities of Drugging the Phosphatidylinositol-3-Kinase/Akt Cell Survival Signaling Pathway 2006 ·Clinical Cancer Research ·Garth Powis, Nathan T. Ihle, D. Lynn Kirkpatrick	33
17	Stability of Phosphoprotein as a Biological Marker of Tumor Signaling 2005 ·Clinical Cancer Research ·Amanda F. Baker, Tomislav Dragovich, Nathan T. Ihle, Ryan Williams, Cecilia M. Fenoglio‐Preiser, Garth Powis	134
18	The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts 2005 ·Molecular Cancer Therapeutics ·Nathan T. Ihle, Gillian Paine-Murrieta, Margareta Berggren, Amanda F. Baker, Wendy R. Tate, Peter Wipf, Robert T. Abraham, D. Lynn Kirkpatrick, Garth Powis	126
19	In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316 2004 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Emmanuelle J. Meuillet, Nathan T. Ihle, Amanda F. Baker, Jaime M.C. Gard, (unknown), Ryan Williams, Amy Coon, Daruka Mahadevan, Benjamin L. George, Lynn Kirkpatrick, Garth Powis	46
20	Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase 2004 ·Garth Powis, Nathan T. Ihle, (unknown), D. Lynn Kirkpatrick, Peter Wipf	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact